KEYNOTE-177: Phase III Trial of First-line Pembrolizumab vs Chemotherapy in MSI-H/dMMR Metastatic CRC

May 29-31, 2020; Online at meetings.asco.org/am
Improvements in both efficacy (PFS, ORR) and safety with single-agent pembrolizumab vs standard therapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 266 KB
Released: June 4, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Daiichi Sankyo, Inc.

Related Content

In this slideset from Clinical Care Options, a panel of international experts review the role of immunotherapy for patients with endometrial cancer.

person default Mansoor Raza Mirza, MD Bradley J. Monk, MD, FACS, FACOG Prof Isabelle Ray Coquard Released: March 2, 2021

Domenica Lorusso, MD, PhD, on the molecular reclassification of endometrial cancers and key ongoing immunotherapy trials, from Clinical Care Options (CCO)

Domenica Lorusso, MD, PhD Released: February 25, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on the integration of CAR T-cell therapy for leukemias, lymphomas, and myeloma

Renier J. Brentjens, MD, PhD Frederick L. Locke, MD Noopur Raje, MD Released: February 18, 2021

From Clinical Care Options (CCO), download slides reviewing the integration of CAR T-cell therapy for leukemias, lymphomas, and myeloma

Renier J. Brentjens, MD, PhD Frederick L. Locke, MD Noopur Raje, MD Released: February 11, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue